洛伐他汀对淀粉样前体蛋白β位点裂解酶表达和活性的影响被引量：1

The study on the effect of lovastatin on the expression and activity of β-site APP cleaving enzyme

下载PDF

导出

摘要目的研究洛伐他汀对淀粉样前体蛋白β位点裂解酶(β-site APP cleaving enzyme,BACE1)表达和活性的影响。方法予洛伐他汀对SH-SY5Y细胞系进行处理;通过噻唑蓝比色(MTT)法观察其对细胞活力的影响;采用酶法测定胆固醇含量,采用荧光光度法测定BACE1活性,采用WesternBlot方法检测BACE1蛋白的表达量。结果与对照组相比,5μmol/L洛伐他汀组作用24h后细胞胆固醇水平下降33.0%(胆固醇与总蛋白含量的比值:3.33vs.4.97;F=5.13,P=0.020),同时BACE1活性下降13.8%(343.14vs.398.22;F=3.773,P=0.035);5μmol/L洛伐他汀组作用48h后细胞胆固醇水平下降49.2%(胆固醇与总蛋白含量的比值:2.65vs.5.22;F=12.239,P=0.001),同时BACE1活性下降38.0%(274.75vs.443.14;F=13.610,P<0.01);洛伐他汀组BACE1蛋白表达量与对照组相比无统计学差异(P>0.05)。结论洛伐他汀不影响BACE1蛋白的表达,但可以抑制BACE1蛋白的活性,同时伴细胞胆固醇水平降低,这为阿尔茨海默病(Alzheimersdisease,AD)的防治提供了新的思路。 Objective To study the effect of lovastatin on the expression and activity of β-site APP cleaving enzyme （BACE1）.Methods The SH-SY5Y cells were treated by lovastatin.Cell viability was assessed by MTT assay,and the levels of cholesterol were assayed spectrophotometrically,and the activity of BACE1 was detected by fluorometric assay,and the expression level of BACE1 was detected by Western Blot.Results Compared with the control group,the cholesterol levels were decreased by 33.0% （3.33 vs.4.97;F=5.13,P=0.020） and the activity of BACE1 was reduced by 13.8% （343.14 vs.398.22;F=3.773,P=0.035） after 24h treatment of 5μmol/L lovastatin;the cholesterol levels were decreased by 49.2% （2.65 vs.5.22;F=12.239,P=0.001） and the activity of BACE1 was reduced by 38.0% （274.75 vs.443.14;F=13.610,P0.01）.Treatment with 5μmol/L lovastatin,for 48 h did affect the expression level of BACE1.Conclusions Lovastatin do not affect the expression level of BACE1,but may inhibit its activity and decrease the cholesterol level,thus providing a new approach to prevent or treat Alzheimer＇s disease （AD）.

作者王芬魏翠柏贾建平

机构地区首都医科大学宣武医院神经内科

出处《中国神经精神疾病杂志》 CAS CSCD 北大核心 2010年第2期80-83,共4页 Chinese Journal of Nervous and Mental Diseases

基金国家973基金资助项目(编号:2006CB500700) 北京自然科学基金重点资助项目(编号:7071004)

关键词淀粉样前体蛋白β位点裂解酶洛伐他汀胆固醇阿尔茨海默病 β-site APP cleaving enzyme Lovastatin Cholesterol Alzheimer disease

分类号 R749.16 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献13

1Vassar R,Bennett BD,Babu-Khan S,et al.Beta-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.Science,1999,286(5440):735-741.
2王芬,魏翠柏,贾建平.降低细胞胆固醇水平对β-淀粉样肽生成的影响[J].脑与神经疾病杂志,2009,17(3):161-164. 被引量：3
3Wolozin B,Kellman W,Rousseau P,et al.Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors[J].Arch Neurol,2000,57(10):1439-1443.
4Green RC,Mcagny SE,Jayakumar P,et al.Statin use and therisk of Alzheimer's disease:the MIRAGE study[J].Alzheimer's Dement,2006,2(2):96-103.
5Fassbender K,Simons M,Bergamann C,et al.Simvastain strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta42 and Abeta40 in vitro and in vivo[J].Proc Natl Acad Sci USA,2001,98(10):5856-5861.
6Simons M,Schwarzler F,Lutjohann D,et al.Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease:A 26-week randomized,placebo-controlled,double-blind trial[J].Ann Neurol,2002,52(3):346-350.
7Kojro E,Gimpl G,Lammich S,et al.Low choesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10[J].PNAS.2001(98):5815-5820.
8Ehehalt R,Keller P,Haass C,et al.Amyloidgenic processing of the Alzheimer beta amyloid precursor protein depends on lipid rafts[J].J Cell Biol,2003,160(1):113-123.
9Cole SL,Grudzien A,Manhart IO,et al.Statins cause intracellular accumulation of amyloid precursor protein,β-secretase-cleaved fragments,and amyloid β-peptide via an isoprenoid-dependent mechanism[J].J Biol Chem,2005,280(19):18755-18770.
10Stephens DJ,Austen BM.Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells[J].J Neurosci Res,1996,46(2):211-225.

二级参考文献10

1Kivipdto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzbeimer's disease in later life: longitudinal, population based study. BMJ, 2001, 322: 1447-1451.
2Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000, 57: 1439-1443.
3Haass C, Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell, 1993, 75 : 1039- 1042.
4Helmuth L. New therapies. New Alzheimer's treatments that may case the mind. Science, 2002, 297:1260-1262.
5Fassbender K, Simons M, Bergamann C, et al. Simvastain strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta42 and Abeta40 in vitro and in vivo. Proc Natl Acad Sci USA, 2001, 98:5856-5861.
6Abad-Rodriguez J, Ledesma MD, Craessaerts K, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol, 2004, 167: 953-960.
7Stein TD, A nders N J, Decarli C, et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPsw mice resulting in tan phosphorylation and loss of hippecampal neurons: support for the amyloid hypothesis. J Neurosci, 2004, 24: 7707-7717.
8Ehehalt R, Keller P, Haass C, et al. Amyloidgenie processing of the Alzheimer beta amyloid precursor protein depends on lipid rafts. J Cell Biol, 2003, 160: 113-123.
9Ikonen E. Roles of lipid rafts in membrane transport. Curr Opin Cell Biol, 2001, 13:470-477.
10周东明.胆固醇缺乏对Jurkat细胞增殖的影响[J].上海免疫学杂志,2003,23(1):24-27. 被引量：1